High levels of debt obligations have led several biotechnology and pharmaceutical companies into financial distress, requiring them to file for bankruptcy and, in many cases, seek sales of their ...

Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse ...

FBT ETF launched 19 years ago and has delivered exceptional returns compared to the broader Health Care sector. Read why FBT ...

Many biotechnology companies can find it challenging to value the sales and marketing contributions made by their pharmaceutical partners, and yet they must be able to do so in order to negotiate ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Royalty Rates in Pharmaceutical and Biotechnology ... Commission by companies and their partners.

Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to ...

Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2025" report ... as submitted to the Securities Exchange Commission by companies and their ...

BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, ...

In biotechnology ... in their industries consistently employ customer insights, performance metrics and real-time analytics to refine strategies and enhance outcomes. Consider tech companies ...

Whether you talk to venture capitalists, potential licensing partners in big pharmaceutical companies, or managers of other biotechnology ... strong yet sensitive to their environment.

as submitted to the Securities Exchange Commission by companies and their partners. This report provides details of the latest partnering deals which disclose a royalty rate announced in the ...